September 27, 2019

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Sirs,

Sub:  Further Updates on Ranitidine Tablets for the US Markets

As advised in our earlier notification to the Stock Exchanges on September 25, 2019, Strides has received an Information Request (IR) from the USFDA to provide test data related to N-nitrosodimethylamine (NDMA) impurities in Ranitidine tablets. This data is to be provided to the agency in 30 days.

While the Company conducts the relevant tests mandated by the USFDA, it has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA.

The Company predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product were ~US$ 9 million in H1FY20.

In spite of this temporary suspension of the ranitidine supplies, the Company retains its FY20 growth outlook for the US markets.

You are requested to take the same on record.

Thanks & Regards,
For Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary